Skip to main content

Table 4 Genes the expression levels of which differed between untreated patients with polymyalgia rheumaticaand untreated controls (FD), and which responded to prednisolone treatment in the patients (FC) (44 genes)

From: Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment

Gene symbol

Gene name

FDa

p

FCb

p

BDNF

brain-derived neurotrophic factor

+1.8

0.016

−3.1

0.001

SVIP

small VCP/p97-interacting protein

+1.7

0.002

−1.7

0.004

TM4SF18

transmembrane 4 L six family member 18

+1.5

0.007

−1.3

0.033

TMTC1

transmembrane and tetratricopeptide repeat containing 1

+1.5

0.001

−1.5

0.003

TMEM18

transmembrane protein 18

+1.5

0.008

−1.4

0.028

N4BP2L1

NEDD4 binding protein 2-like 1

+1.5

0.019

−1.4

0.033

FMO2

flavin containing monooxygenase 2 (non-functional)

+1.5

0.002

−1.4

0.012

RPL37

ribosomal protein L37

+1.5

<0.001

−1.5

<0.001

FAM184B

family with sequence similarity 184, member B

+1.4

0.013

−1.3

0.042

LOC100507303

uncharacterized LOC100507303

+1.4

0.019

−1.6

0.004

RNF114

ring finger protein 114

+1.3

0.016

−1.3

0.030

RERE

arginine-glutamic acid dipeptide (RE) repeats

+1.3

0.003

−1.3

0.008

TUBD1

tubulin, delta 1

+1.3

0.003

−1.4

0.003

ZNF195

zinc finger protein 195

+1.3

0.003

−1.3

0.002

DFFA

DNA fragmentation factor, 45 kDa, alpha polypeptide

+1.3

0.010

−1.2

0.016

RBBP6

retinoblastoma binding protein 6

+1.3

0.004

−1.2

0.025

NPM1

nucleophosmin (nucleolar phosphoprotein B23, numatrin)

+1.3

0.011

−1.2

0.022

EIF4B

eukaryotic translation initiation factor 4B

+1.3

0.017

−1.3

0.015

RSBN1

round spermatid basic protein 1

+1.2

0.003

−1.2

0.016

PSIP1

PC4 and SFRS1 interacting protein 1

+1.2

0.010

−1.3

0.007

EIF3G

eukaryotic translation initiation factor 3, subunit G

+1.2

0.006

−1.3

0.005

PXDC1

PX domain containing 1

+1.2

0.042

+1.5

0.014

BCKDHA

branched chain keto acid dehydrogenase E1, alpha polypeptide

+1.2

0.024

−1.4

0.004

AKR7A2

aldo-keto reductase family 7, member A2

+1.2

0.010

−1.2

0.002

MRPS2

mitochondrial ribosomal protein S2

+1.2

0.018

−1.3

0.006

RORA

RAR-related orphan receptor A

+1.2

0.049

−1.2

0.044

RPL36AL

ribosomal protein L36a-like

+1.2

0.011

−1.2

0.008

PAQR9

progestin and adipoQ receptor family member IX

−2.0

<0.001

+1.4

0.027

FAM69A

family with sequence similarity 69, member A

−1.8

0.001

+1.7

<0.001

TP53INP2

tumor protein p53 inducible nuclear protein 2

−1.8

<0.001

+1.3

0.017

SH3KBP1

SH3-domain kinase binding protein 1

−1.8

0.002

+1.3

0.035

NINJ2

ninjurin 2

−1.7

0.039

+2.3

0.002

MEST

mesoderm specific transcript homolog (mouse)

−1.7

0.010

+2.7

0.049

ITGB1BP2

integrin beta 1 binding protein (melusin) 2

−1.6

<0.001

+1.5

0.003

BPGM

2,3-bisphosphoglycerate mutase

−1.5

<0.001

+1.2

0.036

MTFP1

mitochondrial fission process 1

−1.5

0.004

+1.3

0.017

MAP2K3

mitogen-activated protein kinase kinase 3

−1.5

0.003

+1.3

0.021

LRRN4CL

LRRN4 C-terminal like

−1.4

0.042

+1.5

0.006

FBXO9

F-box protein 9

−1.4

<0.001

+1.3

0.001

JARID2

jumonji, AT rich interactive domain 2

−1.4

<0.001

+1.3

0.007

PRSS23

protease, serine, 23

−1.4

0.030

+1.5

0.022

OLFML2B

olfactomedin-like 2B

−1.4

0.049

+1.7

0.031

MEMO1

mediator of cell motility 1

−1.3

0.004

+1.3

0.012

  1. FD fold difference, FC fold change
  2. a + and −; expression levels were higher and lower, respectively, in patients with polymyalgia rheumatica than in controls before treatment with prednisolone
  3. b + and −; expression levels increased and decreased, respectively, in patients with polymyalgia rheumatica after treatment with prednisolone
  4. Entry in bold indicates that the gene also responded significantly to prednisolone in controls. The response in controls for the RORA gene was of the same magnitude as in patients but in the opposite direction